RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$866M
AUM Growth
+$41.2M
Cap. Flow
-$23.2M
Cap. Flow %
-2.68%
Top 10 Hldgs %
41.18%
Holding
70
New
22
Increased
15
Reduced
16
Closed
15
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$33.3M
2
MCK icon
McKesson
MCK
+$31.1M
3
ADVM icon
Adverum Biotechnologies
ADVM
+$20.8M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$18.6M
5
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$18.1M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$37.6M
2
AGN
Allergan Inc
AGN
+$28.8M
3
ZBH icon
Zimmer Biomet
ZBH
+$26.6M
4
UHS icon
Universal Health Services
UHS
+$26.1M
5
A icon
Agilent Technologies
A
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 75.81%
2 Miscellaneous 18.86%
3 Technology 2.52%
4 Communication Services 1.66%
5 Industrials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IBB icon
51
iShares Biotechnology ETF
IBB
$10.4B
$452K 0.05%
4,956
+1,356
+38% +$119K
2014 Q2
1 quarter
OTIC
52
DELISTED
Otonomy, Inc.
OTIC
$442K 0.05%
+18,400
New +$364K
2014 Q3
0 quarters
PPH icon
53
VanEck Pharmaceutical ETF
PPH
$1.05B
$413K 0.05%
6,500
– –
2013 Q2
5 quarters
IHF icon
54
iShares US Healthcare Providers ETF
IHF
$1.41B
$289K 0.03%
+13,500
New +$288K
2014 Q3
0 quarters
A icon
55
Agilent Technologies
A
$49.1B
– –
-484,938
Closed -$19.9M –
AMGN icon
56
Amgen
AMGN
$230B
– –
-163,254
Closed -$19.3M –
BSX icon
57
Boston Scientific
BSX
$62.3B
– –
-10,000
Closed -$128K –
GERN icon
58
Geron
GERN
$765M
– –
-2,170,288
Closed -$6.58M –
IBB icon
59
PUT
iShares Biotechnology ETF
IBB
$10.4B
– –
-24,000
Closed -$2.06M –
INGN icon
60
Inogen
INGN
$163M
– –
-450,500
Closed -$10.2M –
MDT icon
61
Medtronic
MDT
$121B
– –
-589,974
Closed -$37.6M –
OFIX icon
62
Orthofix Medical
OFIX
$377M
– –
-280,642
Closed -$10.2M –
SYK icon
63
Stryker
SYK
$108B
– –
-213,918
Closed -$18M –
TENX icon
64
Tenax Therapeutics
TENX
$57.3M
– –
0
– -$51K
2014 Q2
1 quarter
ZBH icon
65
Zimmer Biomet
ZBH
$17.5B
– –
-263,735
Closed -$26.6M –
VIRX icon
66
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-48
Closed -$65K –
RXDX
67
DELISTED
Ignyta, Inc.
RXDX
– –
-577,653
Closed -$5.25M –
HTWR
68
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-222,926
Closed -$19.7M –
DSCI
69
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-600,677
Closed -$6.94M –
AGN
70
DELISTED
Allergan Inc
AGN
– –
-170,400
Closed -$28.8M –
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2014 Portfolio in Review

As of Q3 2014, Redmile Group held 70 positions worth $866M, up 5% from $825M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Redmile Group's Q3 2014 filing shows 22 new, 15 increased, 16 reduced and 15 closed positions. Its largest new stake was Celgene Corp: 369,400 shares worth $35M. The largest sale was Medtronic, an estimated $37.6M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Technology.

  • Redmile Group's largest Q3 2014 buy was Celgene Corp: 369,400 shares worth $35M.
  • Redmile Group added most to Rite Aid Corporation in Q3 2014, an estimated $18M increase.
  • Redmile Group's biggest Q3 2014 reduction was Universal Health Services, cutting an estimated $26.1M.
  • Redmile Group fully exited Medtronic in Q3 2014, selling an estimated $37.6M.
  • Redmile Group's ten largest holdings make up 41% of its $866M portfolio in Q3 2014.
  • Redmile Group opened 22 new positions and closed 15 in Q3 2014.
  • Redmile Group's portfolio value rose 5% quarter-over-quarter to $866M.

Based on Redmile Group's 13F filing for Q3 2014, filed 14 Nov 2014.